Analyzing Oncogenes and Resistance in Lung Cancer
Official title: Molecular Analysis of Oncogenes and Resistance Mechanisms in Lung and Other Thoracic Cancers
Run by University of Colorado, Denver · NCT01580982 · Data updated 2026-11-12
This study is trying to find out how certain changes in lung cancer tumors affect how well treatments work, so doctors can make better decisions for patients.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 85 Years |
| Sex | All |
| Enrollment | 500 (estimated) |
| Sponsor | University of Colorado, Denver Academic / other |
| Locations | 1 site (Aurora, Colorado) |
| Status | Recruiting |
| Started | January 23, 2012 |
| Main results expected | January 1, 2028 |
| Study ends | January 30, 2029 |
| Registry record updated | February 18, 2026 |
| Trial ID | NCT01580982 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients aged 18 and older who are being treated for thoracic cancers and undergoing procedures that provide tumor samples for analysis.
✕Probably not a fit
Patients who are not undergoing oncogene-targeted therapies or do not have accessible tumor samples may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study focuses on understanding the mechanisms of sensitivity and resistance to oncogene-targeted therapies in patients with lung and other thoracic cancers. It involves collecting tumor tissue samples from patients undergoing treatment or investigation for these cancers, particularly when there is suspected tumor progression. The goal is to identify somatic changes in the tumor tissue that may influence subsequent treatment decisions based on molecular analysis of the samples.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective treatment strategies for patients with lung cancer.
How similar studies have gone: Other studies have shown success in using molecular analysis to guide treatment decisions in cancer, indicating that this approach is promising.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients undergoing investigation or treatment for thoracic cancers with oncogene-targeted therapies 2. Aged 18 years or older 3. Either a) have suspected tumor progression or other condition that dictates a standard-of-care palliative, therapeutic, or diagnostic intervention including but not limited to procedures such as bronchoscopic biopsy, computed tomography (CT) or ultra-sound (US)-guided biopsy, thoracentesis, video assisted thoracoscopic (VATS) pleurodesis, lobectomy, adrenalectomy or pleural catheter placement, providing tumor specimen appropriate molecular analysis or b) have previously had biopsy/surgical intervention with tumor tissue at University of Colorado or an outside institution available for medullar analysis. 4. Patients must have the ability to understand and willingness to sign an informed consent document. Exclusion Criteria: \-
Where it's running
-
University of Colorado Cancer Center
Aurora, Colorado, United States Recruiting
Study contacts
- Principal investigator: Erin Schenk, MD, PhD — University of Colorado, Denver
- Study coordinator: Brandi Kubala
- Email: brandi.kubala@cuanschutz.edu
- Phone: 303-724-1657
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
AI-assisted longitudinal CT to guide indeterminate lung nodules
This trial tests whether giving doctors an AI report that tracks nodules over serial CT scans helps reduce unnecessary benign lung resections in patients with indeterminate nodules.
-
MRD-guided postoperative monitoring and adaptive treatment for resectable NSCLC
This study tests a personalized follow-up and treatment plan using ctDNA MRD testing and pathology to guide adjuvant therapy after surgery for stage IB-IIIA NSCLC treated with neoadjuvant immunotherapy.
-
Telerehabilitation exercise program after lung cancer surgery
A remote rehabilitation program with guided exercises is tested to help adults after lung cancer surgery recover better.
-
Impact of Exercise on Tumor Immunity in NSCLC Patients Receiving Neoadjuvant Chemo-Immunotherapy
A structured exercise program is being tested to see if it boosts immune cells in the tumor for patients with resectable NSCLC undergoing pre-surgery chemo-immunotherapy.
-
Low-Dose CT Lung Cancer Screening in Kuwait: Feasibility and Uptake
This pilot tests whether offering low-dose CT lung cancer screening to high-risk adults in Kuwait is workable and acceptable, with about 500 participants completing a baseline scan.
-
Nitride-based Raman biochip for lung cancer diagnosis and monitoring
A large observational study in Taiwan will test whether a blood-based nitride-based Raman biochip can help diagnose lung cancer and monitor patients over time.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.